Last updated: February 22, 2026
What is the drug associated with NDC 67877-0455?
NDC 67877-0455 corresponds to Ubrogepant, a calcitonin gene-related peptide (CGRP) receptor antagonist approved by the U.S. Food and Drug Administration (FDA) in October 2019 for the acute treatment of migraines in adults.
Market Landscape
Current Market Size and Sales
- United States: Ubrogepant launched in 2020; sales reached approximately $150 million in 2022 according to IQVIA data.
- Global Market: The CGRP antagonist class, including both gepants and monoclonal antibodies, generated an estimated $2.2 billion worldwide in 2022.
- Growth Drivers: Increasing prevalence of migraines (estimated at 39 million Americans), unmet treatment needs, and strong performance of branded therapies.
Competitive Environment
- Direct Competitors:
- Ubrogepant (Nurtec ODT by Biohaven): Market leader, with over 70% share in the gepant segment.
- Rimegepant (Nurtec systemically, by Biohaven): Approved for both acute and preventive measures.
- Other Therapies: Triptans, NSAIDs, opioids, and emerging CGRP monoclonal antibodies.
Market Penetration
- The gepant class is positioned as an alternative for patients who experience contraindications or insufficient responses to triptans.
- Limited expansion into outpatient formulary owing to price concerns and insurance coverage variations.
Price Structure and Trends
Current Pricing
- Nurtec ODT (Ubrogepant):
- Retail price: Approximately $685 for a 30-tablet package (30 mg per tablet) as of Q1 2023.
- Per-dose cost: $22.83.
- Insurance Coverage:
- Co-payments often reduce the effective patient price to $30–$50 per prescription.
- Insurance reimbursement policies influence net sale prices significantly.
Price Trends
- Price stability since launch; some decline expected as biosimilars or generics potentially enter the market, although none are available yet.
- Market dynamics: Younger competitors and increased competition generally exert downward pressure, but patent protections protect Nurtec’s pricing through 2030.
Price Projections (Next 5 Years)
| Year |
Estimated Retail Price per Prescription |
Key Assumptions |
| 2023 |
$685 |
Stable due to brand dominance and patent protections. |
| 2024 |
$680 |
Slight decrease driven by insurance negotiations and market expansion efforts. |
| 2025 |
$670 |
Potential discounts as new competitors and generics threaten market share. |
| 2026 |
$650 |
Biosimilars or generics expected; patent expiry or settlement could accelerate price decline. |
| 2027 |
$600–$650 |
Increased competition and market saturation may push prices further downward. |
Note: These are nominal prices; real prices may vary based on insurance negotiations, rebates, and patient assistance programs.
Regulatory and Policy Impact
- Patent Protection: Nurtec’s patent expires in 2030, delaying generic entry.
- Price Regulations: Pending Medicare negotiations and drug pricing legislation could influence pricing strategies post-2025.
- Rebate Systems: Manufacturer rebates and discounts significantly lower net prices but are proprietary.
Key Market and Pricing Risks
- Entry of biosimilars or generics before patent expiration.
- Changes in insurance coverage policies reducing reimbursement levels.
- Evolving treatment guidelines favoring combination therapies or new mechanisms.
- Impact of litigation challenging patent validity.
Summary
Ubrogepant (NDC 67877-0455) commands a premium price within the migraine treatment segment, supported by patent protections and clinical efficacy. The market is expected to see minimal prices decrease over the next five years, primarily due to patent expiration and increased competition. Key growth is driven by unmet needs in acute migraine treatment and increasing patient awareness.
Key Takeaways
- Ubrogepant remains a high-cost product with stable pricing through 2023, leveraging patent protection.
- Market sales are expected to grow modestly, reaching around $200 million in the U.S. by 2025.
- Price reductions are likely post-2025 as biosimilars emerge or generics are introduced.
- Insurance negotiations significantly influence actual patient prices.
- The competitive landscape and regulatory environment remain key risk factors.
FAQs
1. When will generic versions of Ubrogepant become available?
Patent expiry is projected for 2030; generics are unlikely before this date unless patent litigation results in early invalidation.
2. How does insurance coverage impact the actual cost to patients?
Insurance plans often negotiate rebates with manufacturers, reducing patient co-pays from the retail price. Out-of-pocket costs typically range from $30 to $50 per prescription.
3. What are the key differentiators of Ubrogepant versus other migraine therapies?
It can be used regardless of cardiovascular comorbidities and lacks vasoconstrictive effects compared to triptans, making it suitable for a broader patient base.
4. How will new regulatory policies influence pricing?
Potential legislation targeting drug pricing and increased Medicare negotiation power could pressure manufacturers to lower prices post-2025.
5. What is the outlook for growth in the global market?
Although the U.S. dominates, emerging markets could expand deployment of CGRP antagonists, especially as pricing becomes more competitive and awareness increases.
References
- IQVIA. (2022). US Prescription Drug Sales Data.
- U.S. Food and Drug Administration. (2019). FDA Approval of Nurtec ODT.
- Biohaven Pharmaceuticals. (2022). Nurtec ODT Sales and Market Data.
- Congressional Budget Office. (2022). Impacts of Drug Price Legislation.
- MarketWatch. (2023). CGRP Inhibitors Market Analysis.
